Conference Coverage

Reports from professional meetings related to NHL.
Proton Therapy in the Management of Non-Hodgkin Lymphoma
Presenter: Bradford Hoppe, MD Presenter's Affiliation: University of Florida Background Non-Hodgkin Lymphoma is a heterogeneous disease with 66,000 new cases each year The disease involves different lymphoid regions of the ..
Gene Expression Profiles in AIDS-Related Lymphomas (ARL): Burkitt Lymphoma (BL) and Diffuse Large B-Cell Lymphoma-Immunoblastic Variant (DLBCL-IBL)
Presenter: Sven de VosPresenter's Affiliation: UCLAType of Session: ScientificBackground Primary CNS lymphoma and other malignant lymphomas continue to be a large problem in patients with AIDS. The most common type ..
Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
This study discusses an off-label use of rituximab for the treatment of MCL. Presenter: W. HiddemannPresenter's Affiliation: Ludwig-Maximilians-University, Munchen, GermanyType of Session: ScientificBackground Mantle cell lymphoma (MCL) accounts for up ..
A pooled analysis of 1,144 patients with HIV-associated lymphoma: Assessment of lymphoma-, HIV-, and treatment-specific factors on clinical outcomes
Presenter: Stefan K. Barta, MD Presenter's Affiliation: Albert Einstein College of Medicine, Bronx, NY Background Patients suffering from HIV are at an increased risk of numerous complications, including several types ..
Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission
Presenter: Sai Ravi Pingali, MD Presenter's Affiliation: Medical College of Wisconsin Affiliated Hospitals, Milwaukee, Wisconsin Abstract #: 8505 Background Hodgkin lymphoma is a fairly uncommon cancer, with ~8,000 cases diagnosed ..
Hodgkin Lymphoma: Improvements in Treatments for Hodgkin Lymphoma Over a 50-Year Period Lead to Fewer Second Malignancies
Presenting Author: Bouthaina Dabaja Presenting Author Affiliation: MD Anderson Cancer Center After receiving a life-saving cancer treatment, the possibility of being diagnosed with a second, new cancer in the years ..
Hodgkin Lymphoma: Cardiovascular Diseases after Hodgkin Lymphoma Treatment: 35-year Disease Risk and Sequence of Events
Presenting Author: Berthe Aleman Presenting Author Affiliation: The Netherlands Cancer Institute The treatment of Hodgkin Lymphoma has transformed over the last 35 years. While curative treatments have been available for ..
Consolidative Proton Therapy in Patients with Hodgkin Lymphoma: Early Outcomes
Presenting Author: Bradford Hoppe, MD Presenting Author Affiliation: University of Florida Proton Therapy Institute, Radiation Oncology, JacksonvilleBackground There are approximately 9000 cases of Hodgkin lymphoma diagnosed annually in the United ..
CHEOP (Chop + Etoposide): the New Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non-Hodgkin's Lymphoma (NHL)
Presenter: Michael G. Pfreundlschuh Presenter's Affiliation: Type of Session: Scientific Background Low Risk (normal LDH)aggressive NHL has classically been treated with CHOP chemotherapy given on a 21 day dosing schedule. ..
Concurrent Fludarabine and Total Body Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkin's Lymphoma (NHL): A Phase I Trial.
Presenter: David Eilender Presenter's Affiliation: Wayne State University Type of Session: Poster Background Both chemotherapy (CHT) and radiation therapy (RT) are used in the treatment of non-Hodgkin's lymphoma (NHL). It ..
Early Restaging Positron Emmision Tomography (PET) with 18F-Fluorodeoxyglucose (18FDG)Predicts Outcome in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL)
Presenter: Karoline Spaepen Affiliation: Leuven, Belgium Background Positron Emission Tomography (PET) with FDG (a radiolabeled sugar molecule) is a nuclear medicine study that is able to detect areas of active ..
High Levels of Soluble CD20 (sCD20) in patients with Non-Hodgkin's Lymphoma (NHL): Correlation with Clinical Behavior and Contrast with Patients with Hodgkin's Disease (HD)
Presenter: M. Albitar Presenter's Affiliation: MD Anderson Cancer Center, Texas Type of Session: Scientific Background CD20 is a Glycoprotein transmembrane receptor found on mature B-cells. Differences in the levels of ..
Advances in Non-Hodgkin's Lymphoma (NHL) Treatment
Conference Dates: September 10, 2004 Conference Location: Audioconference Sponsoring Group: National Marrow Donor Program, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research Conference Web Page ..
Long term follow up of an Alemtuzumab (CAMPATH-1H) containing reduced intensity Allogeneic Transplant Regimen for Non-Hodgkins Lymphoma (NHL)
Presenter: Emma MorrisPresenter's Affiliation: UK Collaborative Group, United KingdomType of Session: ScientificBackground Campath is an antibody that targets CD 52 which is a T cell marker. Campath has been studied ..
Long Term Follow Up of a Phase II study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Aggressive Non-Hodgkins Lymphoma (NHL)
Presenter: J.M. VosePresenter's Affiliation: University of Nebraska Medical CenterType of Session: PosterBackground Standard therapy for NHL is combination chemotherapy with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) Rituxan, a mouse/human anti CD 20 antibody has ..
Modulating IL-2 for Non-Hodgkins' Lymphoma (NHL)
Faculty Disclosure: Michael A. Caligiuri, M.D. This presentation by Dr. Caligiuri discusses off-label use of IL-2 for the treatment of NHL. Presenter: Michael A. Caligiuri, M.D. Affiliation: James Cancer Hospital ..
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)
This presentation discusses the off-label use of rituximab for the treatment of indolent NHL. Presenter: H.S. HochsterPresenter's Affiliation: ECOG/CALGBType of Session: ScientificBackground Indolent lymphomas (IL), as the name implies, have ..
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report
Presenter: Milone, G.Presenter's Affiliation: Instituto de Investigaciones Hematologicas, Buenos Aires, ArgentinaType of Session: ScientificBackground Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated ..
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report
Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated successfully with chemotherapy as well as immunotherapy with or without linked radionuclides. Fludarabine (F) ..
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study
Presenter: Mathias J. Rummel MD, PhD Presenter's Affiliation: Universitaetsklinik, Giessen, Germany Background There are about 25,000 new cases of indolent B-cell lymphoma and mantle cell lymphoma per year, with a ..
Phase I/II Trial Results Of 131-I-Anti-B1 (Anti-CD20) Non-Myeloablative Radioimmunotherapy For Refractory B-Cell Lymphoma
Researchers at the University of Michigan Medical Center (Ann Arbor, MI) presented results of a Phase I/II clinical trial of a new form of treatment for non-Hodgkin's lymphoma. There are ..
A Clinical Trial Of Antigen-Pulsed Dendritic Cells (DC) In The Treatment Of Patients With B-Cell Lymphoma
Researchers at Stanford University Medical Center presented preliminary results of a study on a new vaccine treatment for B-cell lymphoma. Chemotherapy and/or radiation can cause remission in most patients with ..
Single Treatment of Engineered Antibody Demonstrates 100 Percent Response Rate in Follicular Lymphoma
Monoclonal antibodies are small proteins directed against ³marker proteins,² known as antigens, present on the surface of tumor cells. This antibody, known as Anti-B1 Antibody, is directed against CD-20 antigens ..
Myelodysplastic (MDS) Syndrome and Leukemia After Autotransplantation for Lymphoma: a Multicenter Case-Control Study
Presenter: D. J. Rizzo Affiliation: NCI, Bethesda, MD Background: Increased survival has been seen in pateints with Hodgkin?s disease and Non-Hodgkin?s lymphoma who underwent autotransplantation, with a 40-50% long-term disease-free-survival ..
Second Biennial Symposium on Biology, Diagnosis and Treatment of Lymphomas
Conference Dates: Friday, October 4, 2002 Conference Location: Philadelphia Marriott West, 111 Crawford Ave., West Conshohocken, PA Sponsoring Group: University of Pennsylvania Cancer Center Conference Brochure: View the full conference ..
Lymphoma & Myeloma 2002
Conference Dates: October 3 - 5, 2002 Conference Location: New York, New York, USA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/l&m02.htm Topics Covered: Myeloma-Basic Science, Plasma Cell Dyscrasias ..
Lymphoma...the Next Questions
Conference Dates: April 24-25, 2003 Conference Location: San Juan, Puerto Rico Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/lymph_tnq.htm Topics Covered: New Techniques and Treatments, Hodgkin's Disease and Variants, ..
Frankly Speaking about Lymphoma
Conference Dates: Saturday, September 20, 2003 Conference Location: The Wellness Community Philadelphia Sponsoring Group: The Wellness Community Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Special focus on treatment for ..
Treating Advanced Lymphoma
Conference Dates: October 29, 2003 Conference Location: Penn Tower Bridge Level Conference Room Sponsoring Group: Abramson Cancer Center and Leukemia-Lymphoma Society Topics Covered: "Latest Developments in Research and Clinical Applications" ..
Involved-Field Radiotherapy in Patients with Stage III/IV Hodgkin's Lymphoma: First Results of the Randomized EORTC Trial # 20884
Presenter: B.M. Aleman Presenter's Affiliation: EORTC Lymphoma Group, Brussels, Belgium Type of Session: Plenary Background While the role of radiation therapy in the treatment of early stage Hodgkins Disease is ..
Chemotherapy +/- whole-brain irradiation (WBI) for primary CNS lymphoma (PCNSL)-first experience with a randomized trial
Presenter: A. KorfelPresenter's Affiliation: Klinikum Benjamin Franklin, BerlinType of Session: PosterBackground The prognosis of primary CNS lymphoma (PCNSL) is poor. The trend has been to treat without the use of ..
Alternative Targets for Immunotherapy: Targeting CD22 With Monoclonal Antibodies for the Treatment of Non-Hodgkin?s Lymphoma
Presenter: John P. Leonard, MD Affiliation: Cornell University While mortality rates for patients with prostate cancer or breast cancer are decreasing, death rates for patients with non-Hodgkin?s lymphoma continue to ..
Study of Bone Marrow Involvement in 1161 Consecutive Hodgkin's Lymphoma Patients.
Presenter: Alessandro Lewis Affiliation: Piemonte Hodgkin's Disease Registry. Alessandria, Italy Background In Hodgkin's Disease(HD) bone marrow involvement(BMI) has been reported as a unfavorable prognostic factor. Accordingly, bone marrow biopsy(BMB) is ..
Utility of 18-FDG-PET Scanning in Lymphoma by WHO Classification
Presenter: Rebecca L. Elstrom Background: 18-FDG-PET scanning is an important imaging modality in the staging and monitoring of many malignancies, including lymphoma. Some tumors, however, do not have the high ..
Positron Emission Tomography with 18F-FDG in the Evaluation of Post-Treatment Residual Mass in Patients with Malignant Lymphoma.
Presenter: Ralph Naumann Affiliation: University Hospital, Dresden, Germany Background: Management of residual mass after lymphoma treatment is a problematic issue for oncologists. It is not easy to determine if such ..
CHOP Alone Compared to CHOP Plus Radiotherapy for Early Stage Aggressive Non-Hodgkin's Lymphomas: Update of the Southwest Oncology Group (SWOG) Randomized Trial
Presenter: T.P. Miller Presenter's Affiliation: Arizona Cancer Center, Tuscon, AZ Type of Session: Scientific Background In 1998, SWOG study 87-36 reported the results of a randomized trial comparing 8 cycles ..
t(11;18) Is a marker for All Stage Gastric MALT Lymphomas That Will Not Respond o H. Pylori Eradication
Presenter: H. Liu Presenter's Affiliation: Universiy College London Type of Session: Scientific Background Eradication of H. Pylori infection leads to complete regression of gastric mucosa associated lymphoid tissue (MALT)lymphoma in ..
A Randomized Trail of Fludarabine and Mitoxantrone Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma
Presenter: Pier Luigi Zinzani Presenter's Affiliation: Type of Session: Scientific Background Fludarabine plus Mitoxantrone (FM) is an effective combination chemotherapy regimen for the treatment of follicular lymphoma. In this study, ..
Gastric MALT Lymphomas Prospective LY03 Randomized Cooperative Trial: Preliminary Results of the Molecular Follow-up
Presenter: F. Bertoni Presenter's Affiliation: Barts and The London, London Type of Session: Scientific Background Gastric MALT lymphoma is most commonly treated with antibiotic therapy directed at H. Pylori infection. ..
Final Report of E1484: CHOP vs CHOP + Radiotherapy (RT) for Limited Stage Diffuse Aggressive Lymphoma
Presenter: Sandra J. Horning Presenter's Affiliation: Stanford University Type of Session: Scientific Background The objectives of this study were threefold: to determine the rate of complete response (CR) to, and ..
Fludarabine Compared with CVP Chemotherapy in Newly diagnosed Patients with Stages III and IV Low Grade Malignant Non-Hodgkin?s Lymphoma. Final Analysis of a Prospective Randomized Phase III Intergroup Study in 381 Patients
Presenter: A. Hagenbeek Presenter's Affiliation: Type of Session: Scientific Background In 1993, the EORTC lymphoma group initiated a prospective randomized trial in newly diagnosed, low grade non-Hodgkin?s lymphoma (NHL) patients ..
Single Dose Pegfilgrastin (SD/01) Is as Effective as Daily Filgrastim Following ESHAP Chemotherapy for Subjects wtih Non-Hodgkin's Lymphoma or Hodgkin's Disease: Results of a Randomized, Open-Label Study
Presenter: Julie M. Vose Presenter's Affiliation: University of Nebraska Medical Center, Omaha, NE Type of Session: Scientific Background Pegfilgrastim is a pegylated form of filgrastim that has previously been shown ..
Novel Therapeutic Approaches in the Treatment of Multiple Myeloma and Lymphoma
Conference Dates: Friday, February 6, 2004 Conference Location: The St. Regis Hotel, Los Angeles, CA Sponsoring Group: Multiple Myeloma Research Foundation & Lymphoma Research Foundation Conference Web Page URL: www.multiplemyeloma.org/events ..
Lymphoma & Myeloma 2004
Conference Dates: October 14-16, 2004 Conference Location: New York, NY Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: ..
Characterization of the Genomic Breakpoint in t(11:18)(q21:q21) of MALT Lymphoma
Presenter: Hongxiang LiuPresenter's Affiliation: University College LondonType of Session: ScientificBackground The t(11:18)(q21:q21) is the most frequent chromosomal aberration found in mucosa associated lymphoid tissue (MALT) lymphoma. This translocation fuses the ..
High Incidence of t(11:18)(q21:q21) in Helicobacter pylori Negative Gastric MALT Lymphoma
Presenter: Hongtao YePresenter's Affiliation: University College LondonType of Session: ScientificBackground Gastric mucosa associated lymphoid tissue (MALT) lymphoma is strongly associated with H. pylori infection. Only approximately 10% of cases do ..
Primary Pulmonary MALT Lymphomas Show Frequent and Heterogenous Cytogenetic Abnormalities, Including a Previously Unreported MALT1-IGH Translocation
Presenter: Ellen D. RemsteinPresenter's Affiliation: Mayo Clinic; Rochester, MNType of Session: ScientificBackground Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell malignant lymphoma that arises in diverse extranodal sites. t(11;18)(q21;q21), ..
Histological and Clinical Prognostic Factors in Follicular Lymphoma: Proposal for a Prognostic Model
Presenter: Irit AviviPresenter's Affiliation: University College London; UKType of Session: ScientificBackground Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. Despite this, prognostic models to predict ..
Radiotherapy is Unnecessary in Elderly Patients With Localized Aggressive Non-Hodgkin's Lymphoma: Results of the GELA LNH 93-4 Study
Presenter: Georges FilletPresenter's Affiliation: Hematology, CHU - Sart TilmanType of Session: ScientificBackground CHOP plus local radiotherapy is considered the standard treatment for localized, aggressive Non-Hodgkin's Lymphoma (NHL). It has been ..
Superiority of Chemotherapy Alone with the ACVBP Regimen over Treatment with Three Cycles of CHOP Plus Radiotherapy in Low Risk Localized Aggressive Lymphoma: The LNH93-1 GELA Study
Presenter: Felix ReyesPresenter's Affiliation: GELAType of Session: ScientificBackground Chemoradiation is likely the most common form of treatment in patients with aggressive but localized Non-Hodgkin's Disease (NHL). However, published series appear ..
A Multicenter Randomized Trial of Fludarabine and Mitoxantrone (FM) Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma (FL)
Presenter: Pier Luigi ZinzaniPresenter's Affiliation: Italian Cooperative Study Group on LymphomaType of Session: ScientificBackground Follicular lymphoma is a low grade lymphoma that typically has a smoldering disease course. Many patients ..
Two Cycles ABVD Plus Extended Field Radiotherapy Is Superior to Radiotherapy Alone in Early Stage Hodgkin's Disease: Results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7
Presenter: Markus SieberPresenter's Affiliation: University of CologneType of Session: ScientificBackground Extended Field (EF)Radiotherapy alone has been considered the standard for early stage Hodgkin's Disease (HD) with 90% 10 year Overall ..
High Response Rates and Durable Remissions in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma Treated with Tositumomab and Iodine I-131 Tositumomab (Bexxar)
Presenter: Mark S. KaminskiPresenter's Affiliation: University of MichiganType of Session: PosterBackground I-131 Tositumomab is a monoclonal murine antibody directed against the CD20 cell surface protein present on most lymphocytes, including ..
Bexxar Radioimmunotherapy Produces a Substantial Number of Durable Complete Responses in Patients with Multiply Relapsed or Refractory Low Grade or Transformed Low Grade Non-Hodgkin's Lymphoma
Presenter: Mark S. KaminskiPresenter's Affiliation: University of MichiganType of Session: PosterBackground Virtually all patients with low Grade Non-Hodgkin's Lymphoma (LG NHL) relapse. Relapsed or refractory LG NHL is very difficult ..
Epoetin Alfa Treatment Improves Quality of Life and Increases Hemoglobin Levels during Chemotherapy for Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM) Patients with Mild-to-Moderate Anemia
Presenter: David J. StrausPresenter's Affiliation: Memorial Sloan Kettering Cancer Center/ Procrit Hematologic Malignancies Study GroupType of Session: ScientificBackground Anemia affects up to 80% of patients with hematologic malignancies. While the ..
Non-Myeloablative Radio-Immunotherapy With a Iodine-131-Tagged Anti-CD30 Antibody (131I-Ki-4) in Patients With Refractory Hodgkin's Lymphoma
Presenter: Roland SchnellPresenter's Affiliation: University of CologneType of Session: ScientificBackground Relapsed Hodgkin's Disease (HD) has a poor prognosis. More treatment alternatives are neeeded. HD is a good target for immunotherapy ..
Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma
Presenter: J.P. LeonardPresenter's Affiliation: Weill Medical College of Cornell UniversityType of Session: ScientificBackground Bcl-2 overexpression is involved in inhibition of apoptosis and therefore results in tumor cell growth. Bcl-2 is ..
Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas.
Presenter: Owen A. O'ConnorPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: ScientificBackground The ubiquitin proteasome pathway plays an essential role in the degradation of most intracellular proteins in eukaryotic ..
Focus on Leukemia, Lymphoma & Myeloma
Conference Dates: June 24, 2005 Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: The Leukemia & Lymphoma Society, Greater Delaware Valley Division and the Abramson Cancer Center ..
Third Biennial Symposium on Biology, Diagnosis and Treatment of Lymphomas
Conference Dates: Friday, October 14, 2005 Conference Location: Marriott West, West Conshohocken, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Brochure: Download PDF version of conference ..
Mini Allo Transplants for Lymphoma/CLL
Faculty Disclosure: Edwin P. Alyea III, MD Nothing to Disclose Presenter: Edwin P. Alyea III, MD Affiliation: Dana Farber Institute Patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) typically ..
Patient-specific therapeutic vaccines for non-Hodgkin's lymphoma
Faculty Disclosure: John M. Timmerman, M.D. The presentation by Dr Timmerman includes discussion of vaccine therapy that has not been approved by the FDA and the use of GM-CSF as ..
ABVD vs. Stanford V vs. MOPP-EBV-CAD in advanced Hodgkin's lymphoma.  Final results of the IIL HD9601 randomized trial
Presenter: M. FedericoPresenter's Affiliation: Intergruppo Italiano LinfomiType of Session: ScientificBackground The standard treatment for advanced Hodgkin's lymphoma (HL) is ABVD chemotherapy 30% of patients with advanced HL do not respond ..
Randomized intergroup trial of first line treatment for patients </= 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab- early stopping after the first interim analysis
This study discusses an off-label use of rituximab for the treatment of NHL. Presenter: M. G. PfreundschuhPresenter's Affiliation: International Intergroup: Germany, Australia, Sweden, UK, Czech Republic, Canada, Poland, ItalyType of ..
Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD11 trial of the GHSG
Presenter: B.C. KlimmPresenter's Affiliation: German Hodgkin's Study Group (GHSG)Type of Session: ScientificBackground - Combined modality therapy with 4-6 cycles ABVD and Involved Field Radiation (IFRT) is the standard of care ..
First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable of unfavorable early stage Hodgkin's lymphoma (HL)
Presenter: E.M. NoordijkPresenter's Affiliation: EORTCType of Session: ScientificBackground Hodgkin's lymphoma (HL) has an excellent prognosis, yet optimal therapy has still yet to be found Patients are treated based on known ..
HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's Lymphoma.  Interim analysis of a randomized trial of the German Hodgkin's Study Group (GHSG)
Presenter: V. DiehlPresenter's Affiliation: German Hodgkin's Study GroupType of Session: ScientificBackground Patients with early stage Hodgkin's lymphoma (HL) have an excellent prognosis This is especially true in patients without risk ..
Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10
Presenter: R.P. MullerPresenter's Affiliation: Medical University of Vienna, AustriaType of Session: PlenaryBackground Combined modality treatment consisting of few cycles of chemotherapy, usually ABVD, followed by involved field radiotherapy is the ..
ASTRO Patient Summary: Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10
This study looked at patients with early stage (I and II) Hodgkin's disease. There is some controversy over the dose of radiation therapy and the number of cycles of standard ..
Volume of Abnormal Tumor Tissue on FDG-PET -A Predictor of Progression-free Survival in Hodgkin's Lymphoma?
Presenter: Martin HutchingsPresenter's Affiliation: Copenhagen University Hosptial, Copenhagen, DenmarkType of Session: ScientificBackground Pre-treatment tumor volume is a well characterized independent risk factor for developing tumor recurrence in Hodgkin's Lymphoma. PET ..
Motexafin Gadolinium (MGd): Targeting Oxidative Stress Pathways for the Treatment of Non-Hodgkin's Lymphoma
Presenter: Andrew M. Evans, DO, MSCIPresenter's Affiliation: Northwestern University, Chicago, IllinoisType of Session: ScientificBackground Motexafin Gadolinium (MGd or Xcytrin) is a novel anti-cancer agent which disrupts redox- dependent pathways by ..
Lymphoma & Myeloma
Conference Dates: October 18-20, 2007 Conference Location: New York, New York USA Sponsoring Group: Imedex Conference Web Page URL: Imedex.com Topics Covered: Lymphoma Classification, Aggressive Lumphoma, Follicular Lymphomas Conference Objectives: ..
The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma (FL)
Presenter: M.S. Kaminski Presenter's Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MI Type of Session: Scientific Background Follicular lymphoma is an indolent Non-Hodgkin's lymphoma that usually presents in ..
The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation.
Presenter: A.J.Al-Tourah Presenter's Affiliation: BC Cancer Agency Fraser Valley Centre, Surrey, BC, Canada Type of Session: Keynote Background Follicular lymphoma is an indolent Non-Hodgkin's lymphoma that usually presents in an ..
Molecular Evaluation of Telomere length in patients with mantle cell lymphoma (MCL)
Presenter: Cottliar, A.Presenter's Affiliation: Academia Nacional de Medicina, ArgentinaType of Session: ScientificBackground Mantle cell lymphoma (MCL) is a rare (6% of NHL), but aggressive NHL with median survival of 3-4 ..
Cutaneous Lymphomas: Experience of a single institution in Lima-Perú
Presenter: Beltran-Gárate, B.Presenter's Affiliation: Hospital Rebagliati, PeruType of Session: ScientificBackground It has been demonstrated that geographic variations can predict for the clinical behavior and pathologic characteristics of malignant lymphomas. Adult ..
Analysis of 511 Lymphoma Cases in Uruguay
Presenter: Gualco, G. (in Spanish)Presenter's Affiliation: Hospital Militar, Laboratorio de Anatomía Patológica, UruguayType of Session: ScientificBackground The incidence and demographic distribution of Hodgkin's lymphoma (HL) and non-Hodgkin lymphomas (NHL) vary ..
Safety of Intrathecal Rituximab as Prophylaxis or Treatment in CD20+ Acute Lymphoblastic Leukemia (ALL) and Aggressive Lymphoma (AL): Report from a Mexican Pilot Study
Presenter: Villela, L.Presenter's Affiliation: Instituto Nacional de Ciencias Médicas y Nutrición, MexicoType of Session: ScientificBackground CNS involvement in acute lymphoblastic leukemia (ALL) and aggressive lymphoma (AL) is a poor prognostic ..
A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group
Presenter: Cacchione, RPresenter's Affiliation: CEMIC ArgentinaType of Session: ScientificBackground Non-Hodgkin’s Lymphoma (NHL) represents a diverse group of malignancies and has a variable presentation, ranging from indolent to aggressive.  Diffuse large ..
A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group
The purpose of this prospective study was to address the efficacy of Yttrium ibritumomab tiuxetan (Zevalin) in patients with relapsed or refractory lymphomas who had already failed rituximab. Rituximab is ..
Fifth Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia
Conference Dates: September 19-20, 2008 Conference Location: Phoenix, AZ Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/hematologic/5th_mll/index.php Topics Covered: The Fifth Annual Symposium on Controversies and Clinical Challenges ..
Seventh Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia
Conference Dates: September 24-25, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/560 Topics Covered: At the conclusion of this symposium, you should be ..
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
Title: Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial resultsPresenter: S. J. Schuster, MD Affiliation: University of Pennsylvania Non-Hodgkin's Lymphoma (NHL) is the ..
Sexual function in male lymphoma survivors in relationship to age, gonadal hormones and psychosocial issues, and compared to matched controls
Title: Sexual function in male lymphoma survivors in relationship to age, gonadal hormones and psychosocial issues, and compared to matched controls Reviewer: Christine Hill-Kayser, MD Presenter: Cecilie E. Kiserud Affilation: ..
Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm)
Presenter: B. A. Campbell Affiliation: British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma ..
Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial
Presenter: E. Thiel Affiliation: Department of Hematology, Charite Campus Benjamin Franklin, Berlin, Germany Background Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma (NHL). It is ..
Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study
Presenter: M. T. Milano, Department of Radiation Oncology, University of Rochester, Rochester, NY Background Second malignant neoplasms are the leading cause of death among long-term survivors of Hodgkin lymphoma (HL) ..
15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma
Conference Dates: February 17-20, 2011 Conference Location: The Fairmont Château Whistler, 4599 Château Blvd., Whistler, British Columbia, Canada V0N 1B4 Sponsoring Group: Physicians' Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/592 ..
Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) Randomized HD11 Trial
Authors: H. T. Eich, R. P. Mueller, V. Diehl, H. Gorgen, H. Mueller-Hermelink, B. Schmidt, Grosu, J. Karstens, N. Willich, A. Engert Institutions: Department of Radiation Oncology, University of Cologne, ..
Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) is the New Standard of Care in the Treatment of Patients with Early Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) Trial HD10
Authors: R. P. Mueller, H. T. Eich, A. Plutschow, J. Debus, M. Bamberg, K. Wilborn, M. Eble, H. Muller-Hermelink, V. Diehl, A. Engert Institutions: Radioonkologie, Klinikum der Universitaet zu Koeln, ..
Predictors of early response and event-free survival in Hodgkin lymphoma (HL):PET versus CT imaging
Presenter: C. L. Schwartz Presenter's Institution: Hasbro Children's Hospital/Brown University Introduction/Background Response directed therapy is an important concept in the management of Hodgkin Lymphoma (HL). In adult HL, risk stratification ..
Results of a prospective clinical trial for VAMP alone without irradiation for pediatric favorable, early-stage Hodgkin lymphoma patients who achieve an early complete response
Presenter: Monika Metzger, MD Presenter's Affiliation: St. Jude Children's Research Hospital Background Low-risk Hodgkin lymphoma typically refers to stage I-IIA, non-bulky disease in less than 3 sites, and without extranodal ..
Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1)
Presenter: K. Jahnke Presenter's Institution: Charité Hospital, Campus Benjamin Franklin, Berlin, Germany Background CNS lymphoma is rare but incidence is rising in both immunocompetent and imuunocompromised patients. For reference, the ..
Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome
Presenter: Richard Charles Curry, MD Presenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY Background Primary central nervous system lymphoma (PCNSL) is a relatively uncommon variant of extranodal non-Hodgkin lymphoma ..
Patterns of Relapse From a Phase III Study of Response-based Therapy for Intermediate-risk Hodgkin Lymphoma (AHOD0031): A Report from the Children’s Oncology Group
Abstract # 12 Presenter: KV.V. Dharmarajan Presenter's Affiliation: Memorial Sloan Kettering Cancer Center Background Hodgkin’s lymphoma constitutes about 6% of childhood cancers and is most common in children > 10 ..
Second Cancer Risk 40 Years After Hodgkin Lymphoma Treatment
Presenter: Berthe Aleman, MD, PhD Affiliation: The Netherlands Cancer Institute Background Large studies have identified increased risk of breast and other cancers in survivors of Hodgkin lymphoma, partially due to ..
ASH Meeting on Lymphoma Biology
Dates: August 10-13, 2014 Location: Colorado Springs, CO Sponsoring Group: The American Society of Hematology Web Page URL: http://www.hematology.org/Meetings/Lymphoma-Biology-Meeting/11507.aspx Topics Covered: B-cell receptor signaling Germinal center biology Epigenetics of lymphoma ..
Hodgkin Lymphoma: Early Stage Hodgkin Disease Utilization of RT and its impact on OS
Presenting Author: Rahul R. Parikh, MD Presenting Author Affiliation: Mt. Sinai Hospital Cancer patients seek physicians that will provide them with the best available treatment options, especially options with a ..
Dose to Abdominal Organs with Proton Therapy in Diaphragmatic and Infradiaphragmatic Hodgkin Lymphoma
Presenter: Bradford Hoppe, MD Presenter's Affiliation: University of Florida Background Hodgkin Lymphoma typically occurs in young patients age 15-40 years old. Treatment usually involves chemotherapy followed by consolidative radiation therapy. ..

News
Studies outline new options for the standard treatment of various lymphoma types

Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other research being presented will highlight new options for the standard treatment of advanced asymptomatic follicular lymphoma; mantle cell lymphoma; and early, unfavorable Hodgkin's disease.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More



OncoLink Cancer Treatment and Resources